Portfolio

Transforming UK university research into global impact

Meet our companies

The companies we invest in are developing groundbreaking university research into successful businesses, spanning sectors including Life Sciences, AI, Quantum Computing, Advanced Materials, Genomics, CleanTech, Future of Mobility, MedTech and Big Data.

Explore our portfolio

End-to-end in-silico trials solution
adsilico is developing an end-to-end in-silico trials solution based on virtual ‘synthetic patient populations that will provide better and safer medical devices earlier to patients, reduce costs and accelerate R&D timescales for medical device developers, contribute to animal welfare by reducing animal experimentation, reducing refining and partially replacing costly and potentially harmful human trials.
Institution
Leeds
  • Digital Health
  • MedTech

Adsilico

adsilico is developing an end-to-end in-silico trials solution based on virtual ‘synthetic patient populations that will provide better and safer medical devices earlier to patients, reduce costs and accelerate R&D timescales for medical device developers, contribute to animal welfare by reducing animal experimentation, reducing refining and partially replacing costly and potentially harmful human trials.
Sector
Digital Health, MedTech
Institution
Leeds
Website
adsilico.uk

Your Portfolio

If you are an existing investor and want to find out more about your portfolio, visit the investor portal.
Visit Investor Portal

Latest from Parkwalk and our portfolio

4 March 2026

Oxa raises $103m in Series D funding round

Future Mobility
Portfolio
25 February 2026

FT Adviser – The scale-up shift: What’s changing with EIS?

Parkwalk
25 February 2026

Brainomix extends Series C financing to $25.4m

Digital Health MedTech
Portfolio
View all Parkwalk and portfolio news

The products shown on this website will place your capital at risk and investors may not get back the full amount invested. Past performance may not be repeated and is not indicative of future results.

Parkwalk funds invest in smaller and unquoted companies which carry a higher risk than many other forms of investment. There is no guarantee that target returns will be achieved. There is no liquid market for shares in unquoted companies and there can be difficulties, in valuing and disposing of investments in such companies. Tax reliefs will depend on the investors’ individual circumstance and are subject to change.

Parkwalk does not provide investment or tax advice, and the information on this website should not be construed as such. Parkwalk recommends investors seek advice from a regulated financial adviser that specialises in EIS fund investments before making an investment decision. An investment into any of the funds managed by Parkwalk may only be made on the basis of the information set out in the Information Memorandum and Key Information Document.

The information on this website is directed at United Kingdom residents only. Please confirm you have read this warning and are happy to proceed.